Characterization of human p33/41 (annexin VI), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17

Ayano Satoh, Eiji Takayama, Kyoko Kojima, Haruko Ogawa, Yoshimoto Katsura, Tatsuo Kina, Isamu Matsumoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

p33/41 (annexin IV) is a member of the family of Ca2+-dependent phospholipid binding proteins known as annexins. We previously described that bovine kidney p33/41 (annexin IV) has Ca2+-dependent carbohydrate binding activity. In this study, we purified human p33/41 (annexin IV) from the HT29, human colon adenocarcinoma cell line, as well as the bovine kidney annexin by affinity chromatography. Then, we prepared recombinant human p33/41 (annexin IV) expressed in Escherichia coli. The apparent size and the Ca2+-dependent carbohydrate binding properties of purified recombinant p33/41 (annexin IV) were indistinguishable from those of the bovine kidney protein. We also performed inhibition assays of carbohydrate binding and of phosphatidylserine/phosphatidylcholine liposome binding of recombinant p33/41 (annexin IV) with anti-p33/41 monoclonal antibodies (AS11 and AS17). We determined the epitopes recognized by the monoclonal antibodies b) Western blot analysis using deleted-recombinant p33/41 (annexin IV). The monoclonal antibodies recognized domain 1 and/or 2 of p33/41 (annexin IV). The results of the inhibition assays and the determination of the epitope showed that a carbohydrate binding site is located at domains 3 and 4 of p33/41 (annexin IV) and on the cell surface.

Original languageEnglish
Pages (from-to)224-229
Number of pages6
JournalBiological and Pharmaceutical Bulletin
Volume20
Issue number3
Publication statusPublished - Mar 1997
Externally publishedYes

Fingerprint

Annexin A4
Annexin A6
Antibodies
Carbohydrates
Annexins
Monoclonal Antibodies
Kidney
Epitopes
saccharide-binding proteins
Phosphatidylserines
Phosphatidylcholines
Affinity Chromatography
Liposomes
Phospholipids
Carrier Proteins
Colon
Adenocarcinoma

Keywords

  • annexin
  • lectin
  • monoclonal antibody

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Characterization of human p33/41 (annexin VI), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17. / Satoh, Ayano; Takayama, Eiji; Kojima, Kyoko; Ogawa, Haruko; Katsura, Yoshimoto; Kina, Tatsuo; Matsumoto, Isamu.

In: Biological and Pharmaceutical Bulletin, Vol. 20, No. 3, 03.1997, p. 224-229.

Research output: Contribution to journalArticle

Satoh, Ayano ; Takayama, Eiji ; Kojima, Kyoko ; Ogawa, Haruko ; Katsura, Yoshimoto ; Kina, Tatsuo ; Matsumoto, Isamu. / Characterization of human p33/41 (annexin VI), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17. In: Biological and Pharmaceutical Bulletin. 1997 ; Vol. 20, No. 3. pp. 224-229.
@article{eb876c17cfb34f87ae1af6162196722c,
title = "Characterization of human p33/41 (annexin VI), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17",
abstract = "p33/41 (annexin IV) is a member of the family of Ca2+-dependent phospholipid binding proteins known as annexins. We previously described that bovine kidney p33/41 (annexin IV) has Ca2+-dependent carbohydrate binding activity. In this study, we purified human p33/41 (annexin IV) from the HT29, human colon adenocarcinoma cell line, as well as the bovine kidney annexin by affinity chromatography. Then, we prepared recombinant human p33/41 (annexin IV) expressed in Escherichia coli. The apparent size and the Ca2+-dependent carbohydrate binding properties of purified recombinant p33/41 (annexin IV) were indistinguishable from those of the bovine kidney protein. We also performed inhibition assays of carbohydrate binding and of phosphatidylserine/phosphatidylcholine liposome binding of recombinant p33/41 (annexin IV) with anti-p33/41 monoclonal antibodies (AS11 and AS17). We determined the epitopes recognized by the monoclonal antibodies b) Western blot analysis using deleted-recombinant p33/41 (annexin IV). The monoclonal antibodies recognized domain 1 and/or 2 of p33/41 (annexin IV). The results of the inhibition assays and the determination of the epitope showed that a carbohydrate binding site is located at domains 3 and 4 of p33/41 (annexin IV) and on the cell surface.",
keywords = "annexin, lectin, monoclonal antibody",
author = "Ayano Satoh and Eiji Takayama and Kyoko Kojima and Haruko Ogawa and Yoshimoto Katsura and Tatsuo Kina and Isamu Matsumoto",
year = "1997",
month = "3",
language = "English",
volume = "20",
pages = "224--229",
journal = "Biological and Pharmaceutical Bulletin",
issn = "0918-6158",
publisher = "Pharmaceutical Society of Japan",
number = "3",

}

TY - JOUR

T1 - Characterization of human p33/41 (annexin VI), a Ca2+ dependent carbohydrate-binding protein with monoclonal anti-annexin IV antibodies, AS11 and AS17

AU - Satoh, Ayano

AU - Takayama, Eiji

AU - Kojima, Kyoko

AU - Ogawa, Haruko

AU - Katsura, Yoshimoto

AU - Kina, Tatsuo

AU - Matsumoto, Isamu

PY - 1997/3

Y1 - 1997/3

N2 - p33/41 (annexin IV) is a member of the family of Ca2+-dependent phospholipid binding proteins known as annexins. We previously described that bovine kidney p33/41 (annexin IV) has Ca2+-dependent carbohydrate binding activity. In this study, we purified human p33/41 (annexin IV) from the HT29, human colon adenocarcinoma cell line, as well as the bovine kidney annexin by affinity chromatography. Then, we prepared recombinant human p33/41 (annexin IV) expressed in Escherichia coli. The apparent size and the Ca2+-dependent carbohydrate binding properties of purified recombinant p33/41 (annexin IV) were indistinguishable from those of the bovine kidney protein. We also performed inhibition assays of carbohydrate binding and of phosphatidylserine/phosphatidylcholine liposome binding of recombinant p33/41 (annexin IV) with anti-p33/41 monoclonal antibodies (AS11 and AS17). We determined the epitopes recognized by the monoclonal antibodies b) Western blot analysis using deleted-recombinant p33/41 (annexin IV). The monoclonal antibodies recognized domain 1 and/or 2 of p33/41 (annexin IV). The results of the inhibition assays and the determination of the epitope showed that a carbohydrate binding site is located at domains 3 and 4 of p33/41 (annexin IV) and on the cell surface.

AB - p33/41 (annexin IV) is a member of the family of Ca2+-dependent phospholipid binding proteins known as annexins. We previously described that bovine kidney p33/41 (annexin IV) has Ca2+-dependent carbohydrate binding activity. In this study, we purified human p33/41 (annexin IV) from the HT29, human colon adenocarcinoma cell line, as well as the bovine kidney annexin by affinity chromatography. Then, we prepared recombinant human p33/41 (annexin IV) expressed in Escherichia coli. The apparent size and the Ca2+-dependent carbohydrate binding properties of purified recombinant p33/41 (annexin IV) were indistinguishable from those of the bovine kidney protein. We also performed inhibition assays of carbohydrate binding and of phosphatidylserine/phosphatidylcholine liposome binding of recombinant p33/41 (annexin IV) with anti-p33/41 monoclonal antibodies (AS11 and AS17). We determined the epitopes recognized by the monoclonal antibodies b) Western blot analysis using deleted-recombinant p33/41 (annexin IV). The monoclonal antibodies recognized domain 1 and/or 2 of p33/41 (annexin IV). The results of the inhibition assays and the determination of the epitope showed that a carbohydrate binding site is located at domains 3 and 4 of p33/41 (annexin IV) and on the cell surface.

KW - annexin

KW - lectin

KW - monoclonal antibody

UR - http://www.scopus.com/inward/record.url?scp=0030892570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030892570&partnerID=8YFLogxK

M3 - Article

C2 - 9084877

AN - SCOPUS:0030892570

VL - 20

SP - 224

EP - 229

JO - Biological and Pharmaceutical Bulletin

JF - Biological and Pharmaceutical Bulletin

SN - 0918-6158

IS - 3

ER -